

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Day 1 Summary

Linus Chuang MD MPH MS
Professor, Gynecologic Oncology
Icahn School of Medicine at Mount Sinai
New York NY

Cervix Cancer Education Symposium, January 2017, Mexico

Gynecologic Cancer InterGroup Cervix Cancer Research Network



- Welcome and opening remarks - Dr. Meneses and Dra. Gallardo
- Introduction of participants
 - One third are conducting clinical trials
- What's CCRN - Dr. Gaffney
 - Improve education in care and clinical research
 - Supports 4 ongoing clinical trials
 - Develop new trials
- Cervical cancer: a global perspective - Dr. Poveda
 - Calls for prevention and to improve survival as a priority

Gynecologic Cancer InterGroup Cervix Cancer Research Network



- Radiation Hope - Dr. Fisher
 - Provide and update radiation equipment in developing countries through fund raising
- Varian: emerging markets - Mr. Pollatz
 - Treating cervical cancer without brachytherapy has an inferior survival
 - Provides technical and educational supports
- Elect: emerging markets - Ms. de Bekker
 - Promising results from image guided brachytherapy

Gynecologic Cancer InterGroup Cervix Cancer Research Network



- Advaxis and Stendhal presentations: Mr. Duke
 - Develop targeted immunotherapies
 - Listeria generated T cell responses
 - AXAL Phase 2 trial and AIM2CERV trial in Cervical Cancer
- IGCS perspective- Dr. Covens
 - New web site
 - New education programs
 - Calls for new members to join IGCS
 - Calls for new editor-in-chief for IJGC

- IAEA perspective - Dr. Wahab
 - Global cancer plan aims at decreasing death from cancer
 - Develop guidelines
 - Supports education, quality assurance, clinical trials etc
- Management of cervical cancer in resource limited settings
 - ASCO and NCCN resource stratified guidelines
- Reports of survey - Dr. Gaffney
 - Clinical practice information

Gynecologic Cancer InterGroup Cervix Cancer Research Network



- Global cervical cancer - Dr. Trimble
 - Trials: 1 vs 2 doses of HPV vaccination, new ablative technology
 - Clinical research initiative for global health
 - Affordable cancer technology
 - A cost effective IMRT delivery for LMIC
- Good clinical Practice and QA compliance - Dr. Bacon
- Beyond platinum: concurrent chemotherapy in cervix cancer - Dr. Dueñas González
 - Gemcitabine plus cisplatin chemoradiotherapy followed by BCT and adjuvant gemcitabine/cisplatin chemotherapy improved survival outcomes with increased but clinically manageable toxicity when compared with standard treatment.

Gynecologic Cancer InterGroup Cervix Cancer Research Network



- Neoadjuvant chemotherapy in cervix cancer - Dra. Gomez
 - Benefits and review of trials
- SLN in cancer of the cervix - Dr. Plante
 - Clinical application of SLN detection
- Role of surgery in cervical cancer - Dr. Cantu
 - Surgery is not going away
 - More research is needed

Gynecologic Cancer InterGroup Cervix Cancer Research Network



- Biomarkers in cervix cancer - Dr. Plasencia
 - Gene signatures to predict responses
 - Transcriptome analysis helps distinguish clinical responses
- Immunotherapy in treatment of cervix cancer - Dr. Mileskin
 - Adoptive cellular transfer
 - Active immunotherapy
 - Axalimogene Filolisbac (discussed further today)
 - Check point inhibitors
 - Ipilimumab, Nivolumab, Pembrolizumab